John A. Ellerton
Expertise in
10
conditions

Dr. John A. Ellerton

Hematology | Oncology
3175 Saint Rose Pkwy Ste 200, 
Henderson, NV 
On Staff At
Accepting New Patients
Referral required
Expertise in
10
conditions
3175 Saint Rose Pkwy Ste 200, 
Henderson, NV 

Overview

John Ellerton is a Hematologist and an Oncologist practicing medicine in Henderson, Nevada.

Dr. Ellerton is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Hemochromatosis, Colorectal Cancer, Breast Cancer, Tissue Biopsy, and Bone Marrow Aspiration.

Dr. Ellerton is board certified in American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 5 peer reviewed articles and participating in 155 clinical trials. Dr. Ellerton is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in NV

Board Certifications

American Board Of Internal Medicine

Hospital Affiliations

Centennial Hills Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

Optum Cancer Care
3175 Saint Rose Pkwy Ste 200, Henderson, NV 89052

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

155 Clinical Trials

Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: April 14, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug
Study Drugs: Atezolizumab, Talazoparib
Study Phase: Phase 2
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Drug
Study Drugs: Endoxifen Hydrochloride, Tamoxifen Citrate
Study Phase: Phase 2
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 2
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Olaparib, Pembrolizumab
Study Phase: Phase 2
View 9 Less Clinical Trials

5 Total Publications

OPERA: a phase II study of DHP107 (oral paclitaxel) versus intravenous paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer.
OPERA: a phase II study of DHP107 (oral paclitaxel) versus intravenous paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer.
Journal: Breast cancer research and treatment
Published: January 05, 2026
Similar Doctors
Expertise in
46
conditions
Dr. Hamdy Mohtaseb
Hematology | Oncology
Expertise in
46
conditions
Dr. Hamdy Mohtaseb
Hematology | Oncology

Arthritis Associates Of Nevada

8905 S Pecos Rd Ste 23A, 
Henderson, NV 
 (11.4 miles away)
702-361-3030
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Hamdy Mohtaseb is a Hematologist and an Oncologist practicing medicine in Henderson, Nevada. Dr. Mohtaseb is highly rated in 46 conditions, according to our data. His clinical expertise encompasses Juvenile Primary Osteoporosis, Hemochromatosis, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Colorectal Cancer.

Expertise in
2
conditions
Dr. Michael D. Becker
Hematology | Oncology
Expertise in
2
conditions
Dr. Michael D. Becker
Hematology | Oncology

Optum Cancer Care

3980 S Eastern Ave, 
Las Vegas, NV 
 (10.4 miles away)
702-463-9100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Becker is a Hematologist and an Oncologist practicing medicine in Las Vegas, Nevada. Dr. Becker is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Familial Prostate Cancer and Prostate Cancer. Dr. Becker is board certified in American Board Of Radiology. Dr. Becker is currently accepting new patients.

Expertise in
18
conditions
Dr. Nicholas Vogelzang
Oncology
Expertise in
18
conditions
Dr. Nicholas Vogelzang
Oncology

Comprehensive Cancer Centers Of Nevada

3730 S Eastern Ave, 
Las Vegas, NV 
 (10.5 miles away)
702-952-3400
Languages Spoken:
English
See accepted insurances

Nicholas Vogelzang is an Oncologist practicing medicine in Las Vegas, Nevada. Dr. Vogelzang is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Renal Cell Carcinoma (RCC), Urothelial Cancer, Orchiectomy, and Nephrectomy.

Frequently Asked Questions about Dr. John A. Ellerton

How do I make an appointment with Dr. John A. Ellerton?

You can book an appointment with Dr. John A. Ellerton by calling their office at 702-724-8787. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. John A. Ellerton a top-rated expert for Hemochromatosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. John A. Ellerton is classified as an Advanced expert for Hemochromatosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. John A. Ellerton specialize in?

While Dr. John A. Ellerton is a Hematology, they have specific expertise in Hemochromatosis, Colorectal Cancer, and Breast Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. John A. Ellerton participate in research or clinical trials?

Yes. Dr. John A. Ellerton has published 5 articles and abstracts on conditions like Hemochromatosis. You can view a list of Dr. John A. Ellerton's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. John A. Ellerton accept my insurance?

Dr. John A. Ellerton accepts most major insurance plans, including Aetna and Cigna. We recommend calling the office directly at 702-724-8787 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ellerton's expertise for a condition
ConditionClose
      View All 10 Advanced Conditions
      View All 123 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile